Equipment Price Wars Benefit Genetics Labs
Posted on: Thursday, 21 December 2006, 12:12 CST
An old-fashioned price war between two U.S. companies selling gene-scanning machines could accelerate forward-looking genetic research, researchers said.
Rivals Affymetrix of Santa Clara, Calif., and Illumina Inc. of San Diego sell equipment for high through-put genotyping -- a market worth between $200 million to $350 million, The Wall Street Journal said Thursday. Most of its growth, estimated between 25 percent and 40 percent, is in gene chips and scanners used to find genes linked to cancer, asthma, autism and other conditions.
The scanners seek to identify genes that predispose people to chronic diseases such as heart disease, cancer or neurodegenerative conditions. The machines are big-ticket purchases labs consider every three to five years.
Both companies last summer began cutting the price for their gene chips to gain market share, the Journal said.
Researchers told the newspaper that affordability means they can do more, bigger or different scans, boosting the chances to find genes related to diseases. Even the California-based companies said a competitive marketplace benefits patients because the competition drives innovation.
Source: United Press International
Related Articles
- Jumping Genes, Gene Loss And Genome Dark Matter
- Gene Signal Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth
- ACMG Joins Lawsuit Challenging Patents on Breast Cancer Genes; Genes Are Naturally Occurring Substances and Should Not Be Patented, Says American College of Medical Genetics
- Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform
- Does Gene Show Connection Between Migraine And Stroke Or Heart Attacks?
- GENEART Presents the Industrial Production of Genes, Gene Li-Braries and Genomes at the Biotechnica
- Aida Acquires Shanghai Gene Therapy Company
- Barr Pharmaceuticals Inc, a Company Analysis Including 16 Deals Made, and 21 Partnering Companies Between 2000 and 2005
- 24 Deals Made By Watson Pharmaceuticals Inc and Its Subsidiaries With 25 Partnering Companies Between 2000 and 2005
- Researchers Discover Mechanism Linking Color Vision and Cancer Genes
User Comments (0)

RSS Feeds